Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)

Next Previous
Trial Profile

Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Datopotamab deruxtecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms TROPION-PanTumor01
  • Sponsors AstraZeneca; Daiichi Sankyo Company

    • Most Recent Events

    • 27 Jan 2024 Preliminary Results (At data cutoff (May 18, 2023), n=18) assessing safety and efficacy of Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer presented at the 2024 Genitourinary Cancers Symposium
    • 15 Jun 2023 Planned number of patients changed from 770 to 890.
    • 19 Apr 2023 Results from substudy analyzing association between stomatitis and treatment efficacy of datopotamab deruxtecan, presented at the 114th Annual Meeting of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top